2008 Breast Cancer Symposium
Integrating Emerging Science into Clinical Practice

---

Friday, September 5, 2008

---

Exhibit Hall Open
7:00 AM – 6:45 PM

Continental Breakfast Provided
7:00 AM – 8:00 AM

Welcome
7:45 AM – 8:00 AM

General Session I: Risk, Screening, and Prevention
8:00 AM – 9:30 AM
Co-Chairs: Steven E. Harms, MD – The Breast Center of Northwest Arkansas
Sheldon Marc Feldman, MD, FACS – Beth Israel Medical Center

Magnetic Resonance Imaging for Breast Screening: Who Are the Candidates and How Should It Be Done?
Susan G. Orel, MD – University of Pennsylvania

Risk Prediction for Breast Cancer: Pearls and Perils
Lynn C. Hartmann, MD – Mayo Clinic

Genetic Risk Factors for Breast Cancer
Judy E. Garber, MD, MPH – Dana-Farber Cancer Institute

Environmental Risk Factors for Breast Cancer
Melissa L. Bondy, PhD – M. D. Anderson Cancer Center

Pharmacologic Prevention: Beyond Anti-Estrogens
Powel Brown, MD, PhD – Baylor College of Medicine

Question and Answer Panel

Break
9:30 AM – 10:00 AM

General Session II: Angiogenesis and Insulin-like Growth Factor Receptor: New Targets in Breast Cancer
10:00 AM – 12:00 PM
Co-Chairs: Anna Maria Storniolo, MD – Indiana University Melvin and Bren Simon Cancer Center
Debu Tripathy, MD – Physicians Education Resource

Anti-Angiogenic Therapy: From Bench to Bedside
George W. Sledge, Jr., MD – Indiana University Melvin and Bren Simon Cancer Center

Angiogenesis: What is the Target?
Robert S. Kerbel, PhD – Sunnybrook Health Sciences Centre

Potential Synergies Between Targeting Hormone Receptor Signaling and Angiogenesis
Maura N. Dickler, MD – Memorial Sloan-Kettering Cancer Center

Insulin and Insulin-like Growth Factor Signaling: Basic Science and Clinical Relevance to Breast Cancer
Michael Pollak, MD – McGill University

Drugs to Target Insulin-like Growth Factor Receptor
Lyndsay N. Harris, MD – Yale University School of Medicine

Question and Answer Panel

General Poster Session A (Box Lunches Provided)
12:00 PM – 1:15 PM
Selected topicrelated abstracts will be on display, with the authors available for informal discussion.
Poster walks will be held during this session – ticket required.

ASCO Gianni Bonadonna Breast Cancer Award & Lecture
1:15 PM – 2:00 PM

Oral Abstract Presentation Session A
2:00 PM – 3:15 PM
Co-Chairs: Lisa A. Newman, MD, MPH – University of Michigan
Matthew P. Goetz, MD – Mayo Clinic

ABSTRACT: Estradiol (E2) suppression with monthly versus 3-monthly goserelin treatment in premenopausal patients with early breast cancer
H. Iwata – Aichi Cancer Center Hospital

ABSTRACT: Disease associations of fgfr2, tnrc9, and map3k1 polymorphisms in breast cancer
Amy Martin – University of Dundee

ABSTRACT: Contralateral prophylactic mastectomy and survival
Isabelle Bedrosian, MD – University of Texas M. D. Anderson Cancer Center

Discussant: Susan M. Domchek, MD – University of Pennsylvania Abramson Cancer Center

ABSTRACT: Calcium plus vitamin D supplement use, 25-Hydroxyvitamin D (25 OHD) levels and breast cancer risk in the Women's Health Initiative (WHI)
Rowan T. Chlebowski, MD, PhD – Los Angeles Biomedical Research Institute

Break
3:15 PM – 3:45 PM

General Session III: Radiation: Basics and Beyond
3:45 PM – 5:30 PM
Co-Chairs: Lori J. Pierce – University of Michigan Medical School
Meena S. Moran, MD – Yale University School of Medicine

Prognostic Factors for Breast-Conserving Therapy: How They Affect Local Control
Lawrence J. Solin, MD, FACR – Albert Einstein Medical Center

Hypofractionated Radiotherapy: Rationale and Clinical Applications
Timothy J. Whelan, BM, BCh, MSc – McMaster University and Juravinski Cancer Center

Postmastectomy Radiotherapy: Current Indications
Reshma Jagsi, MD, PhD – University of Michigan

Technical Innovations to Decrease Late Radiation Toxicity
Lawrence B. Marks, MD – University of North Carolina at Chapel Hill

Radiosensitization: Preclinical Models and Clinical Applications
Silvia C. Formenti, MD – New York University Medical Center

Question and Answer Panel

Reception and General Poster Session B (Wine and Cheese Provided)
5:30 PM – 6:45 PM
Selected topicrelated abstracts will be on display, with the authors available for informal discussion.

Tumor Board: Early Stage Breast Cancer
Ticket Required
6:00 PM – 7:00 PM
Chair, Shelley Hwang, MD, MPH – University of California San Francisco Carol Franc Buck Breast Care Center

Lawrence J. Solin, MD, FACR – Albert Einstein Medical Center
Hyman B. Muss, MD – University of Vermont and Vermont Cancer Center
Kimberly J. Van Zee, MD – Memorial Sloan-Kettering Cancer Center
Ann D. Thor, MD – University of Colorado Denver
Wendie A. Berg, MD, PhD – Johns Hopkins Green Spring

---

Saturday, September 6, 2008

---

Exhibit Hall Open
7:00 AM – 6:45 PM

Continental Breakfast Provided
7:00 AM – 8:00 AM

Fellows, Residents, Trainees, and Junior Faculty Breakfast
7:00 AM – 8:00 AM
Chair: Sunil Verma, MD, MSc, FRCSC – Sunnybrook Odette Cancer Centre
Ticket Required

Welcome and Break
8:00 AM – 8:15 AM

General Session IV: Triple-Negative Breast Cancer: Whats Positive?
8:15 AM – 10:00 AM
Co-Chairs: Ann D. Thor, MD – University of Colorado Denver
Angelo Di Leo, MD – Hospital of Prato

Biological Underpinnings of Triple-Negative Disease
Daniel Silver, MD, PhD – Harvard Medical School

Pathology and Molecular Classification
Andrea Richardson, MD, PhD – Brigham and Womens Hospital

Metabolomic Alterations and Breast Cancer
Ann D. Thor – University of Colorado Denver

Is There an Optimal Chemotherapy for Triple-Negative Disease?
Martine J. Piccart, MD, PhD – Jules Bordet Institute

ABSTRACT: Triple receptor-negative breast cancer: The effect of race on response to primary systemic treatment and survival outcomes
Shaheenah S Dawood, MD – Department of Health and Medical Services

ABSTRACT: New highlights on the biological, clinical, and prognostic implications of p53 transcriptional status in breast cancers
Tarek M Abdel-Fatah, BM, BCh, MSc – University of Nottingham

Question and Answer Panel

Break
10:00 AM – 10:30 AM

General Session V: Selected Controversies in Pathology
10:30 AM – 12:00 PM
Co-Chairs: William Fraser Symmans, MD – M. D. Anderson Cancer Center
Shawna C. Willey, MD, FACS – Georgetown University Hospital

Lobular Neoplasia: Current Controversies
Jean F. Simpson – Vanderbilt University Medical Center

ABSTRACT: Molecular heterogeneity among sentinel lymph node metastases: Implications for the sentinel node hypothesis
Darrell L. Ellsworth, PhD – Windber Research Institute

What are the Implications of Intratumoral Heterogeneity?
Edi Brogi, MD, PhD – Memorial Sloan-Kettering Cancer Center

ABSTRACT: Two-year evaluation of clinical use of an intraoperative RT-PCR assay for the detection of metastases in sentinel lymph nodes of patients with breast cancer at the Institut Jules Bordet
J. Schobbens – Institut Jules Bordet

Intraoperative Evaluation of Sentinel Nodes
Peter W. Blumencranz, MD, FACS – Morton Plant Mease Healthcare

Abstract Presentation

Question and Answer Panel

General Poster Session C (Box Lunches Provided)
12:00 PM – 1:15 PM
Selected topicrelated abstracts will be on display, with the authors available for informal discussion.
Poster walks will be held during this session – ticket required.

General Session VI: Keynote: Self-Seeding
1:15 PM – 2:00 PM
Introduction, Clifford Hudis, MD – Memorial Sloan-Kettering Cancer Center
Eric Winer, MD – Dana-Farber Cancer Institute

Self-Seeding
Joan Massagué, PhD – Memorial Sloan-Kettering Cancer Center
Larry Norton, MD – Memorial Sloan-Kettering Cancer Center

Question and Answer Panel

Oral Abstract Presentation Session B
2:00 PM – 3:30 PM
Co-Chairs: Jay R. Harris, MD – Dana-Farber Cancer Institute
Eleftherios Mamounas, MD – Aultman Cancer Center

ABSTRACT: Concordance between HER2 RNA and protein expressions and relationship between topoisomerase 2A RNA expression and recurrence after adjuvant doxorubicin- containing chemotherapy for operable breast cancer.
Joseph A. Sparano, MD – Montefiore-Einstein Cancer Center

ABSTRACT: Determination of HER2 status in patients achieving less than a pathologic complete response following neoadjuvant therapy with combination chemotherapy plus trastuzumab
Elizabeth A. Mittendorf, MD – University of Texas M. D. Anderson Cancer Center

Discussant: Hope Rugo, MD – University of California, San Francisco

ABSTRACT: Establishment of a Breast Cancer Atlas for radiation therapy (RT) planning
Julia White, MD – Medical College of Wisconsin

ABSTRACT: Effect of docetaxel-based adjuvant chemotherapy on disease-free survival in patients with high-risk node-negative breast cancer: Results from the geicam 9805 trial
Miguel Martin, MD, PhD – Hospital Clinico San Carlos

Break
3:30 PM – 4:00 PM

General Session VII: Challenges in Survivorship
4:00 PM – 5:30 PM
Co-Chairs: Don S. Dizon, MD, FACP – Women & Infants' Hospital/Alpert Medical School of Brown University
Helen A. Pass, MD, FACS – Lawrence Hospital

Appropriate Standards for Follow Up Care
Hyman B. Muss, MD – University of Vermont and Vermont Cancer Center

Survivorship Issues in Younger Women
Ann H. Partridge, MD, MPH – Dana-Farber Cancer Institute

Survivorship Issues in Older Women
Arti Hurria, MD – City of Hope

Breast Cancer: Cognitive Concerns
Patricia A. Ganz, MD – University of California Los Angeles

Lymphodema: Progress and Challenges
Janice N. Cormier, MD, MPH, FACS – M. D. Anderson Cancer Center

Question and Answer Panel

Reception and General Poster Session D (Wine and Cheese Provided)
5:30 PM – 6:45 PM
Selected topicrelated abstracts will be on display, with the authors available for informal discussion.

Tumor Board: Metastatic Disease
Ticket Required
6:00 PM – 7:00 PM
Chair, Andrew D. Seidman, MD – Memorial Sloan-Kettering Cancer Center

Timothy J. Whelan McMaster – University and Juravinski Cancer Center
Martine J. Piccart, MD, PhD – Jules Bordet Institute
George W. Sledge, Jr., MD – Indiana University Melvin and Bren Simon Cancer Center
Harry D. Bear, MD, PhD – Virginia Commonwealth University

---

Sunday, September 7, 2008

---

Tumor Board: Locally Advanced Breast Cancer
Ticket Required
7:00 AM – 8:00 AM
Chair, Eleftherios Mamounas, MD – Aultman Cancer Center

Silvia C. Formenti, MD – New York University Medical Center
Lyndsay N. Harris, MD – Yale University School of Medicine
Emiel J. Rutgers, MD, PhD – Netherlands Cancer Institute
William Fraser Symmans, MD – M. D. Anderson Cancer Center
Susan G. Orel, MD – University of Pennsylvania
Nagi F. Khouri, M.D – The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

General Poster Session E (Continental Breakfast Provided 7:00 AM 8:10 AM)
7:00 AM – 12:00 PM
Selected topicrelated abstracts will be on display, with the authors available for informal discussion.
Poster walks will be held during this session – ticket required.

Welcome
8:10 AM

General Session VIII: Keynote: Healthcare in Developing Countries
8:15 AM – 8:45 AM
Introduction, Clifford Hudis, MD – Memorial Sloan-Kettering Cancer Center
Eric Winer, MD – Dana-Farber Cancer Institute

Oncology Treatments in Developing Nations
Samir Khleif, MD – National Cancer Institute

General Session IX: Breast Cancer Therapy: Underserved Communities Around the World
8:45 AM – 10:00 AM
Co-Chairs: José Colón, MD – Hospital Auxilio Mutuo
Nancy Davidson, MD – Sidney Kimmel Cancer Center at Johns Hopkins

Clinical Care in the Developing World: The India Example
Vineet Gupta, MD – Health Care Global Enterprises

Breast Cancer in Latin America
Eduardo L. Cazap, MD – SLACOM

Breast Care Guideline Implementation in Low and Middle Income Countries
Benjamin O. Anderson, MD – University of Washington

Clinical Research in the Developing World
Richard R. Love, MD, MS – The Ohio State University School of Medicine

Question and Answer Panel

Break
10:00 AM – 10:15 AM

General Session X: Multidisciplinary Implications of Preoperative Therapy
10:15 AM – 12:00 PM
Co-Chairs: Eleanor Harris, MD – H. Lee Moffitt Cancer Center
Sandra M. Swain, MD – Washington Cancer Institute

Developing Predictors for Neo-adjuvant Therapy
Lajos Pusztai, MD, DPhil – M. D. Anderson Cancer Center

Can We Tailor Chemotherapy Based on Preliminary Response?
Gunter von Minckwitz, MD, PhD – GBG Forschungs GmbH; J. W. Goethe – Universität Frankfurt am Main

Surgical Management and Staging of Breast Cancer Treated with Neoadjuvant Chemotherapy
Harry D. Bear, MD, PhD – Virginia Commonwealth University

Evaluating Specimens After Pre-operative Therapy
Susan C. Lester, MD – Brigham and Womens Hospital

Are There Patients Who Should Not Receive Pre-operative Therapy?
Funda Meric-Bernstam, MD – M. D. Anderson Cancer Center

ABSTRACT: European Cooperative Trial in Operable Breast Cancer (ECTO): no increased risk of Local Breast Tumor Recurrence (LBR) as first and only event after Primary Systemic Therapy (PST) and conservative surgery
Wolfgang Eiermann, MD – Fondazione Michelangelo

Question and Answer Panel